跳到正文
原文
Endpoints News· @endpts · X·· 29 天前AI 评分42
AI 导读

独家:赛诺菲选中ScionxBio为其筛选mRNA候选药物,这是该初创公司自Eleven Therapeutics拆分以来的首笔交易。https://endpoints.news/sanofi-taps-new-startup-scionxbio-for-long-acting-rna/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial

正文

Exclusive: Sanofi tapped ScionxBio to screen its mRNA candidates, the startup’s first deal since splitting from Eleven Therapeutics. https://endpoints.news/sanofi-taps-new-startup-scionxbio-for-long-acting-rna/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial

来源:Endpoints News · x.com